HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China OTC Drug Sales Pummeled By Pseudoephedrine Restrictions

This article was originally published in The Tan Sheet

Executive Summary

Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.

You may also be interested in...



Sales & Earnings In Brief

Sanofi now world’s No. 3 OTC player; Glaxo weighs Lucozade energy drink divestment; NBTY wraps Balance Bar integration; Vicks launches in Europe boost Teva OTC business; flu trend breeds cautious optimism for Prestige Brands; USANA and Nu Skin face tough times for multilevel marketers.

Bayer Increases Chinese Presence With Topsun Cough/Cold Buy

Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel